"Effects of intensive glucose lowering in type 2
diabetes,"
by the ACCORD Study Group (H.C. Gerstein, et al.), New England
Journal of Medicine, 358(24): 2545-59, 12 June 2008.
[Authors' affiliations: For the Writing Group, 10 U.S. and Canadian
institutions]
Abstract: "Background: Epidemiologic
studies have shown a relationship between glycated hemoglobin levels and
cardiovascular events in patients with type 2 diabetes. We investigated
whether intensive therapy to target normal glycated hemoglobin levels would
reduce cardiovascular events in patients with type 2 diabetes who had
either established cardiovascular disease or additional cardiovascular risk
factors. Methods: In this randomized study, 10,251
patients (mean age, 62.2 years) with a median glycated hemoglobin level of
8.1% were assigned to receive intensive therapy (targeting a glycated
hemoglobin level below 6.0%) or standard therapy (targeting a level from
7.0 to 7.9%). Of these patients, 38% were women, and 35% had had a previous
cardiovascular event. The primary outcome was a composite of nonfatal
myocardial infarction, nonfatal stroke, or death from cardiovascular
causes. The finding of higher mortality in the intensive-therapy group led
to a discontinuation of intensive therapy after a mean of 3.5 years of
follow-up. Results: At 1 year, stable median glycated
hemoglobin levels of 6.4% and 7.5% were achieved in the intensive-therapy
group and the standard-therapy group, respectively. During follow-up, the
primary outcome occurred in 352 patients in the intensive-therapy group, as
compared with 371 in the standard-therapy group (hazard ratio, 0.90; 95%
confidence interval [CI], 0.78 to 1.04; P=0.16). At the same time, 257
patients in the intensive-therapy group died, as compared with 203 patients
in the standard-therapy group (hazard ratio, 1.22; 95% CI, 1.01 to 1.46;
P=0.04). Hypoglycemia requiring assistance and weight gain of more than 10
kg were more frequent in the intensive-therapy group (P<0.001).
Conclusions: As compared with standard therapy, the use of
intensive therapy to target normal glycated hemoglobin levels for 3.5 years
increased mortality and did not significantly reduce major cardiovascular
events. These findings identify a previously unrecognized harm of intensive
glucose lowering in high-risk patients with type 2 diabetes."
This 2008 report from the New England Journal of Medicine was
cited 72 times in current journal articles
indexed by Clarivate during September-October 2009. As was the case
during the previous count for July-August, the report registers as the
second-most-cited medicine paper published in the last two years, aside
from reviews. Prior to the most recent bimonthly count, citations to the
paper have accrued as follows:
SOURCE:
Hot Papers Database (Included with a subscription to the print
newsletter
Science Watch®, available from the
Research Services
Group of Thomson
Reuters. Packaged on a CD that is mailed with each Science
Watch issue, the Hot Papers Database contains data on hundreds of
highly cited papers published during the last two years. User interface
permits searching by author, organization, journal, field, and more. Total
citations, as well as citations accrued during successive bimonthly
periods, can be assessed and graphed. An updated CD containing the most
recent bimonthly data is mailed with every new issue of Science
Watch, six times a year. The CD also includes an electronic version of
the Science Watch issue in HTML format, for personal desktop
access.